MiMedx Group (MDXG) Q4 2024 earnings summary

Executive summary

• Achieved 9% full-year revenue growth and 7% Q4 growth, reaching $93 million in Q4 and $349 million for the year.

• Maintained high gross profit margin at 82% in Q4 and delivered adjusted EBITDA of $20 million (21% of sales) in Q4 and $76 million (22% of sales) for the year.

• Ended the year with $104 million in cash, up $16 million in Q4, and generated $65 million in free cash flow for the year.

• Q4 GAAP net income was $7 million ($0.05/share); full-year net income was $42 million.

• Management remains confident in growth opportunities despite Medicare reimbursement disruptions.

Financial highlights

• Q4 gross profit was $76 million (82% margin); adjusted gross margin was 84%.

• Full-year gross profit was $289 million (83% margin); adjusted gross margin was 84%.

• Q4 SG&A expenses rose to $61 million, mainly due to higher compensation, commissions, and legal/regulatory costs.

• R&D expenses were $4 million in Q4 and $12 million for the year, focused on clinical trials and product development.

• Q4 net cash from operations was $18.8 million; full-year net cash from operations was $66.2 million.

Outlook and guidance

• 2025 guidance assumes LCDs implemented as scheduled on April 13, with expected net sales growth in the high single digits and adjusted EBITDA margin above 20%.

• Longer-term, targets low double-digit top-line growth and sustained adjusted EBITDA margin above 20%.

• Revenue and EBITDA expected to be lowest in Q1, highest in Q4, with Q2 and Q3 similar.

• Expects higher growth rates in the back half of 2025 post-LCD implementation.